Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices 41455 

Dated: August 7, 2009. 

Lisa J. Lierheimer, 

Senior Permit Biologist, Branch of Permits, 

Division of Management Authority. 

[FR Doc. E9–19579 Filed 8–14–09; 8:45 am] 

BILLING CODE 4310–55–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Modified Consent 

Decree Pursuant to the Clean Air Act 

Notice is hereby given that on August 

11, 2009, a proposed modified Consent 

Decree in United States et al. v. Ohio 

Edison Co., et al., (S.D. Ohio), No. C2– 

99–1181, was lodged with the United 

States District Court for the Southern 

District of Ohio. The proposed modified 

Decree is incorporated within a Joint 

Motion to Modify Consent Decree with 

Order Modifying Consent Decree, filed 

the same day in the same court. 

Under the proposed modified Consent 

Decree, Ohio Edison agrees to repower 

one of its coal-fired power plants—the 

R.E. Burger Generating Station Units 4 

and 5 (‘‘Burger’’) near Shadyside, 

Ohio—using primarily renewable 

biomass fuel. The agreement, joined by 

the States of New York, Connecticut and 

New Jersey, modifies a 2005 consent 

decree requiring reductions in Ohio 

Edison’s emissions of sulfur dioxide 

(‘‘SO2’’) and nitrogen oxide (‘‘NOX’’). 

The modified decree will substantially 

reduce emissions of SO2 and NOX from 

Burger’s current levels and significantly 

reduce net carbon dioxide emissions 

from current levels. 

The Department of Justice will receive 

for a period of thirty (30) days from the 

date of this publication comments 

relating to the modified Consent Decree. 

Comments should be addressed to the 

Assistant Attorney General, 

Environment and Natural Resources 

Division, and either e-mailed to 

pubcomment-ees.enrd@usdoj.gov or 

mailed to P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611, and should refer to United 

States et al. v. Ohio Edison, et al., (S.D. 

Ohio.), No. C2–99–1181, D.J. Ref. 90–5– 

2–1–06894. The modified Consent 

Decree may be examined at the Office of 

the United States Attorney, Southern 

District of Ohio, 280 North High Street, 

Fourth Floor, Columbus, Ohio 43215. 

During the public comment period, the 

modified Consent Decree may also be 

examined on the following Department 

of Justice Web site, http:// 

www.usdoj.gov/enrd/ 

Consent_Decrees.html. A copy of the 

modified Consent Decree may also be 

obtained by mail from the Consent 

Decree Library, P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611 or by faxing or e-mailing a 

request to Tonia Fleetwood 

(tonia.fleetwood@usdoj.gov), fax no. 

(202) 514–0097, phone confirmation 

number (202) 514–1547. In requesting a 

copy from the Consent Decree Library, 

please enclose a check in the amount of 

$2.50 (25 cents per page reproduction 

cost) payable to the U.S. Treasury. 

Maureen Katz, 

Deputy Chief, Environmental Enforcement 

Section. 

[FR Doc. E9–19564 Filed 8–14–09; 8:45 am] 

BILLING CODE 4410–15–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (09–072)] 

Notice of Intent To Grant Partially 

Exclusive License 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of intent to grant 

partially exclusive license. 

SUMMARY: This notice is issued in 

accordance with 35 U.S.C. 209(c)(1) and 

37 CFR 404.7(a)(1)(i). NASA hereby 

gives notice of its intent to grant an 

exclusive license worldwide to practice 

the invention described and claimed in 

U.S. Patent No. 7,094,045, 

entitled‘‘Microencapsulation System 

and Method’’, U.S. Patent No. 7,295,309, 

entitled ‘‘Microparticle Analysis System 

and Method’’ to NuVue Therapeutics, 

Inc. (formerly known as Critical Care 

Innovations, Inc.), having its principal 

place of business in Fairfax, Virginia. 

The fields of use are for both clinical 

and veterinary applications in the 

production and applications of 

microcapsules and microencapsulation 

of all cyto-toxic anti-cancer drugs. Also 

included are externally-triggered 

microcapsules including the use of 

ultrasound and magnetic flux triggering 

technologies, in situ activation inside 

microcapsules, cell encapsulation, and 

urokinase and DNA measurement of 

metastasis for diagnostic testing. The 

patent rights in these inventions have 

been assigned to the United States of 

America as represented by the 

Administrator of the National 

Aeronautics and Space Administration. 

The prospective partially exclusive 

license will comply with the terms and 

conditions of 35 U.S.C. 209 and 37 CFR 

404.7. 

DATES: The prospective partially 

exclusive license may be granted unless, 

within fifteen (15) days from the date of 

this published notice, NASA receives 

written objections including evidence 

and argument that establish that the 

grant of the license would not be 

consistent with the requirements of 35 

U.S.C. 209 and 37 CFR 404.7. 

Competing applications completed and 

received by NASA within fifteen (15) 

days of the date of this published notice 

will also be treated as objections to the 

grant of the contemplated exclusive 

license. 

Objections submitted in response to 

this notice will not be made available to 

the public for inspection and, to the 

extent permitted by law, will not be 

released under the Freedom of 

Information Act, 5 U.S.C. 552. 

ADDRESSES: Objections relating to the 

prospective license may be submitted to 

Patent Counsel, Office of Chief Counsel, 

Mail Code AL, 2101 NASA Parkway, 

Houston, TX 77058, (281) 483–4871; 

(281) 483–6936 [Facsimile]. 

FOR FURTHER INFORMATION CONTACT: 

Theodore U. Ro, Patent Attorney, Office 

of Chief Counsel, Johnson Space Center, 

Mail Code AL, 2101 NASA Parkway, 

Houston, TX 77058, (281)244–7148; 

(281)483–6936 [Facsimile]. Information 

about other NASA inventions available 

for licensing can be found online at 

http://technology.nasa.gov/. 

Dated: August 7, 2009. 

Richard W. Sherman, 

Deputy General Counsel. 

[FR Doc. E9–19487 Filed 8–14–09; 8:45 am] 

BILLING CODE P 

NUCLEAR REGULATORY 

COMMISSION 

[Docket No.: 70–1151; NRC–2009–0355; EA– 

08–244; License No.: SNM–1107] 

In the Matter of Westinghouse Electric 

Company LLC; Confirmatory Order 

(Effective Immediately) 

I 

Westinghouse Electric Company LLC 

(WEC or Licensee) is the holder of 

Operating License No. SNM–1107 

issued by the Nuclear Regulatory 

Commission (NRC or Commission) 

pursuant to 10 CFR part 70. The license 

in effect at the time of the matters 

described below was most recently 

amended via Amendment 5, issued on 

April 10, 2009. The license authorizes 

the operation of WEC in accordance 

with the conditions specified therein. 

The facility is located on the Licensee’s 

site in Columbia, South Carolina. 

This Confirmatory Order is the result 

of an agreement reached during an 

Alternative Dispute Resolution (ADR) 

mstockstill on DSKH9S0YB1PROD with NOTICES